No evidence of bone metastases (M) on bone scan within  days prior to registration (sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute)\r\n* Equivocal bone scan findings are allowed if plain films (or CT or magnetic resonance imaging [MRI]) are negative for metastasis
Bony metastatic lesions must be =<  cm in maximum dimension and evaluable on either a computed tomography (CT) or magnetic resonance imaging (MRI) scan; metastatic lesions in the spine must involve =<  contiguous vertebral bodies
The subject has had an assessment of all known non-CNS disease sites e.g., by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within  days before the first dose of cabozantinib
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within  days before the first dose of cabozantinib
Metastatic disease by bone scan or other nodal or visceral lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
Metastatic disease identified via radiographic assessment by computed tomography (CT) scans of the chest, abdomen, pelvis, and nuclear bone scan; magnetic resonance imaging (MRI) may be used if deemed necessary by the investigator; more specifically, patients must have at least one of the following at time of study enrollment:\r\n* Any visceral metastases identified by CT scans or MRI\r\n* Site(s) of bony metastasis identified by nuclear bone scan, MRI, and/or CT scan\r\n* Lymph node based disease not considered to be within a single radiation therapy port (e.g. at or above the aortic bifurcation)
Metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan
Individuals with distant metastases or clinically or pathologically involved lymph nodes are ineligible; if suspected, they must be ruled out by computed tomography (CT), pelvic magnetic resonance imaging (MRI), or bone scan within  days of study entry
Metastatic disease documented prior to randomization by clear evidence of bone lesions on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v.
Patients must have staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan, and CT scan or x-ray of the chest within  days prior to registration; if the alkaline phosphatase is > . x upper limit of normal (ULN), there is a presence of suspicious bone pain, or if there is other clinical suspicion of bone metastases, a whole body bone scan is required within  days prior to registration
Evidence of metastatic disease on imaging studies (computed tomography [CT] and/or bone scan)
Stage D disease with documented biochemical progression documented by rising PSA and no evidence of metastatic disease by physical examination, computed tomography (CT) scan or bone scan
Histologically confirmed, metastatic prostate adenocarcinoma (positive bone scan and/or measurable disease on computed tomography [CT] scan and/or magnetic resonance imaging [MRI] of the abdomen and pelvis)
Magnetic resonance imaging (MRI) pelvis, computed tomography (CT) pelvic, or bone scan for a PSA >= . ngs/ml may be done, based on the physician preference
Metastatic disease documented by at least one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI)
Evidence of metastasis by magnetic resonance imaging (MRI)/computed tomography (CT) scan, bone scan, or histologic confirmation
Metastatic disease by bone scan or other nodal or visceral lesions on CT or MRI at any time (past or present).
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Radiographic confirmation of oligometastatic diagnosis via bone scan validated by either computed tomography (CT) scan or magnetic resonance imaging (MRI) within the past  days
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans).
Evidence of metastatic disease to the bone seen on most recent bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
No evidence of metastatic disease as documented by technetium-m (mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
No radiographic evidence of metastatic disease by computed tomography (CT) scan and bone scan, performed within the prior  weeks
Bone disease documented by either: a positive bone scan, computed tomography (CT) scan, or magnetic resonance imaging (MRI); or biopsy proven bony metastases
Subjects must have metastatic disease detectable by either bone scan or cross sectional imaging by CT or magnetic resonance imaging (MRI) as per the PCWG guidelines
Metastatic disease radiographically documented by CT or bone scan
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans)
Has staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within  weeks prior to treatment initiation
Evidence of metastatic disease: minimum imaging required Computed tomography scan (CT) / Magnetic Resonance Imaging (MRI) and Whole Body Bone Scan (WBBS). If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
The subject has had an assessment of all known disease sites e.g, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within  days before the first dose of cabozantinib
Radiographic evidence of metastatic disease; computed tomography (CT) and bone scan must be performed with  days (+  days) of registration; magnetic resonance imaging (MRI) of brain can be performed within  months prior to registration
Radiographic evidence of metastatic disease documented with bone scan or computed tomography (CT) scan\r\n* Patients with any number of metastatic site are allowed to enroll; however, only up to six sites will be selected for stereotactic body radiation therapy (SBRT) treatment, at the discretion of the treating radiation oncologist
Local, locally advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Patients must have shown unequivocal radiographic evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan; a scan should be performed within  days prior to registration and on a steroid dose that has been stable or decreasing for at least  days; if the steroid dose is increased between the date of imaging and registration a new baseline MRI/CT is required; the same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement; measurable disease is NOT required\r\n* Note: MRI is the preferable imaging method; CT scan may be used in cases where an MRI cannot be obtained
Tumor volume occupies less than % of liver by volume as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) scan within  weeks of treatment
Patients with evidence on prior imaging (bone scan, CT, or MRI) suggestive of disseminated disease will not be eligible (imaging not required for eligibility)
Evidence of distant metastasis; (determined by computed tomography [CT] scan, magnetic resonance imaging [MRI], and/or bone scan prior to the simulation appointment; imaging results from University of Pennsylvania Health System [UPHS] will supersede results from similar scans from an outside facility)
Metastatic disease documented by CT/MRI or bone scan (not older than  days at enrollment) revealing at least one metastatic lymph-node, visceral metastasis and/or bone metastasis
The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within  days before the first dose of cabozantinib
Metastatic disease as demonstrated by bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI) of the pelvis, or chest x-ray
Assessable disease with a positive bone scan and/or measurable disease on computed tomography (CT) scan and/or magnetic resonance imaging (MRI) of the abdomen and pelvis
Patients must have metastatic disease radiographically documented by CT/magnetic resonance imaging (MRI) or bone scan; measurable disease is not necessary for inclusion
Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, computed tomography (CT) scan or magnetic resonance imaging (MRI); (patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible)
Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen or pelvis
Patients must have staging scans with abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) scan and CT scan or x-ray of the chest within  days prior to registration; if alkaline phosphatase is above the treating institutions upper limit of normal (ULN), presence of suspicious bone pain, or if other clinical suspicion, a whole body bone scan is required within  days prior to registration
Radiological or clinical evidence (bone scan, computerized tomography [CT], and magnetic resonance Imaging [MRI]) of recurrence or progression within  days before randomization
Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.
Metastatic disease documented by greater than or equal to (>=)  bone lesions on mTc bone scan. Participants with a single bone lesion must have confirmation of bone metastasis by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have metastatic prostate cancer (clinical stage D or D disease), with previously documented lymph node, soft tissue and/or bone metastases by radiographic imaging (including computed tomography [CT] [or magnetic resonance imaging (MRI)] of abdomen and pelvis and bone scintigraphy); patients in situations in which there is a reasonable clinical suspicion of a second primary tumor (or other non-prostate cancer reason for radiographic abnormalities) are not eligible unless metastatic disease is histologically confirmed to be prostate cancer
Evidence of metastatic disease in bone on bone scan, CT scan, and/or by MRI at any time following the initial diagnosis of prostate cancer
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Evidence of lymph node or bone metastasis by magnetic resonance imaging (MRI)/computed tomography (CT), bone scan, or biopsy (NMx or NxM)
Metastatic disease as documented by technetium-m (mTc) bone scan or metastatic lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans (visceral or lymph node disease). If lymph node metastasis is the only evidence of metastasis, it must be greater than or equal to (>=)  centimeter (cm) in the longest diameter
Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician)
Evidence of metastatic disease by radiographic imaging (bone scan or other nodal or visceral lesions on computed tomography [CT] or magnetic resonance imaging [MRI])
Any evidence of extraocular retinoblastoma clinically or by magnetic resonance imaging (MRI) of brain and orbits with and without gadolinium; MRI may be done within  days prior to study entry\r\n* Evidence of systemic metastases on bilateral bone marrow, lumbar puncture, bone scan (or fludeoxyglucose F- [FDG] positron emission tomography [PET] scan), and/or any other additional tests done at study entry; (Note: these tests are required only with specific indications for required observations)
Evidence of metastatic disease on previous bone scan, computed tomography (CT) scan and/or magnetic resonance imaging (MRI)
Presence of existing lytic bone lesions either by skeletal X-ray, computed tomography (CT) scan or magnetic resonance imaging (MRI) scan
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT), magnetic resonance imaging (MRI); if lymph node metastasis is the only evidence of metastasis, it must be >=  cm in diameter
Negative computed tomography (CT) scan/magnetic resonance imaging (MRI) and bone scan for metastatic prostate cancer
Metastatic disease documented by one of the following:\r\n* Metastatic bone disease on an imaging study, or\r\n* Soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI), or
Local, locally-advanced, or metastatic disease documented as having shown progression on a scan (e.g., computed tomography [CT], magnetic resonance imaging [MRI])
Radiographic evidence of metastatic disease, detectable by bone scan, CT scan, or MRI. At least one site of metastatic disease must be amenable to needle biopsy.
Known brain metastasis or evidence of metastatic disease by computed tomography (CT) scan, physical exam, or bone scan within  weeks of registration\r\n* Patients with equivocal uptake on a bone scan that in the clinician's opinion do not definitively constitute metastatic disease are eligible
Documented evidence of M disease by American Joint Committee on Cancer (AJCC) staging by bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI)
Metastatic disease on imaging (e.g., bone scan, computed tomography [CT], magnetic resonance imaging [MRI]); patients whose disease spread is limited to regional pelvic lymph nodes are not eligible; if lymph node metastasis is the only evidence of metastasis, it must be >=  cm in diameter
Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine which may include computer assisted tomography (CAT scan), positron emitted tomography (PET) or nuclear medicine bone scan (NMBS); magnetic resonance imaging (MRI) is required prior to treatment planning to confirm the extent of the disease and is used for defining the target for the radiation
Appropriate stage for protocol entry, based upon the following minimum diagnostic workup:\r\n* History and physical examination, including a complete list of current medications\r\n* Chest x-ray (posteroanterior [PA] and lateral views)\r\n* Abdominal/pelvic computed tomography (CT) scan\r\n* Brain magnetic resonance imaging (MRI) if clinically indicated\r\n* Bone scan if clinically indicated
No evidence of metastatic disease on physical exam, computed tomography (CT)/magnetic resonance imaging (MRI)/chest x-ray (CXR), and bone scan within  weeks prior to randomization
Histological documentation of local recurrence or metastasis is strongly encouraged, unless the risk of such a procedure outweighs the potential benefit of confirming the metastatic disease; if no histologic confirmation, then the metastases or recurrence will require documentation by a nd radiographic procedure (eg. PET/computed tomography [CT] scan or magnetic resonance imaging [MRI] in addition to the CT scan); if the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation will be required
Patients must have clinical stage T-Ta and no radiographic evidence of metastatic disease as demonstrated by:\r\n* EITHER computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis, OR endorectal MRI of the pelvis that demonstrate no nodes > . cm\r\n* If one or more pelvic lymph node(s) measures > . cm, a negative biopsy is required; if more than one lymph node is > . cm, the largest or most accessible node should be biopsied; AND\r\n* Negative bone scan (with plain films and/or MRI and/or CT scan confirmation, if necessary)\r\nPositive positron emission tomography (PET) and ProstaScint scans are not considered proof of metastatic disease
Metastatic disease documented by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan.
Metastatic Disease with at least one lesion on bone scan and/or soft tissue on CT/MRI
Every patient with relapse or progression into the CNS must be documented with computed tomography (CT) scan or MRI of the brain; other sites of relapse may be evaluated, including bone marrow
Presence of metastatic disease (M) as assessed by computed tomography/ magnetic resonance imaging (CT/MRI) and/or whole-body radionuclide bone scan.
Pain must be from one or two painful metastatic sites in the bone (additional less painful metastatic sites may be present)\r\n* Pain from the reported one or two metastatic sites must correlate with an identifiable tumor on CT, magnetic resonance imaging (MRI), or ultrasound (US) imaging\r\n* Metastatic tumors must be amenable to cryoablation with CT or MRI
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI) scan.
Patients with either skeletal pain or alkaline phosphatase that is > ULN must have a bone scan showing they do not have metastatic disease; suspicious findings on bone scan must be confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy
Documented metastatic disease on bone scan, computed tomography (CT) scan or magnetic resonance imaging (MRI)
Appropriate diagnosis for protocol entry, based upon the following minimal diagnostic work-up:\r\n* History/physical examination within  weeks prior to registration and:\r\n* Suspicion of metastatic cancer to the vertebrae or multiple myeloma with a focus in a vertebral body(ies) and;  \r\n* The lesion must be identifiable with radiologic evidence (x-ray, bone scan, computed tomography [CT] scan, magnetic resonance imaging [MRI])
Locally advanced, unresectable, and/or metastatic soft-tissue sarcoma of intermediate or high grade with evidence of disease progression by either computed tomography (CT) or magnetic resonance imaging (MRI) scan, or clinical judgment on or after the last cancer therapy within  months prior to randomization.
No evidence of metastatic disease on imaging by whole body bone scan (technetium- or sodium fluoride [Na-F] positron emission tomography [PET] bone scan) and cross-sectional imaging of the abdomen/pelvis (computed tomography [CT] or magnetic resonance imaging [MRI]) within  weeks of day  of protocol therapy
Evidence of metastatic disease on bone scan or MRI/computed tomography (CT)
Metastatic disease documented by bone, computed tomography (CT), or magnetic resonance image (MRI) scan
No evidence of metastatic disease as documented by technetium-m (mTc) bone scan and by computed tomography (CT) or magnetic resonance imaging (MRI) scans
Patients with any radiographic evidence of metastases, including plain x-ray, bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or positron emission tomography (PET) scan
Radiographic evidence* of bone metastases within  weeks of study for non-weight bearing sites and  weeks for weight bearing sites; the patient must have pain which appears to be related to the radiographically documented metastasis in the opinion of the treating physician, and the decision has been made by the responsible clinician that a course of palliative external beam radiation therapy is appropriate treatment; multiple sites eligible if they can be included in no greater than  treatment sites and not all identifiable lesions will require treatment unless they are painful lesions\r\n* This should be one of the following:  plain film, bone scan, positron emission tomography (PET) scan, computed tomography (CT) scan, or magnetic resonance imaging (MRI)
Metastatic bone disease with metastatic disease previously confirmed by prior biopsy; or Metastatic bone disease previously confirmed on imaging [e.g. computed tomography (CT) or magnetic resonance imaging (MRI)] with known (biopsied) primary disease (primary bone cancer is excluded)
Undergone standard of care conventional imaging (computed tomography [CT] and/or magnetic resonance [MR]; bone scan and/or sodium fluoride [NaF] PET)
Biopsy proven or clinically documented metastatic breast cancer with at least one lesion outside the liver by standard imaging (e.g. CT, magnetic resonance imaging [MRI], bone scan, ultrasound, fludeoxyglucose F  [FDG] PET/CT)
At least  metastatic soft tissue or osseous lesions identified on conventional imaging (CT, magnetic resonance imaging [MRI] or bone scan)
No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and/or negative cross section imaging (MR or CT)
Patients with distant metastatic disease beyond N (regional) lymph nodes on conventional imaging studies (computed tomography [CT], MRI or bone scan)
Recurrent or metastatic cancer that is of known or suspected breast origin - may be biopsy proven or identified on standard imaging (e.g. CT, bone scan, magnetic resonance imaging [MRI], FDG PET/CT)
Subjects with advanced disease who have failed hormone therapy and who have sufficient tissue (obtained before or after  weeks of Eovist injection) from a soft tissue or metastatic bone lesion (measuring >= . cm in diameter at computed tomography [CT] or MRI scan) available for OATPB expression or
imaging modalities (bone scan, MRI or CT) OR
Presence of at least one measurable or detectable metastasis as defined by bone scintigraphy, computed tomography (CT) scan appearance (magnetic resonance imaging [MRI] if indicated), or plain x-ray appearance
